134 completed. 134 Phase 3, 12 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 134 | Completed 134 |
| Phase 2 | 12 | Completed 12 |
Follow Myeloproliferative Disorders: new trials by email Literature Review of Myeloproliferative Disorders trials Research Report on Myeloproliferative Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate P1101 in Japanese PV Patients P1101, Low-dose aspirin, Phlebotomy - Polycythemia Vera (PV) | Phase 3 | Completed | PharmaEssentia Japan K.K. | 21 | 2023-10-17 | 2024-11-08 |
| Asciminib Treatment Optimization in ≥ 3rd Line CML-CP ABL001 40mg BID, ABL001 80mg QD, ABL001 200mg QD - Chronic Myelogenous Leukemia | Phase 3 | Completed | Novartis Pharmaceuticals | 199 | 2021-10-13 | 2026-03-18 |
| Asciminib in Monotherapy for Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With and Without T315I Mutation ABL001 - Chronic Myelogenous Leukemia - Chronic Phase | Phase 3 | Completed | Novartis Pharmaceuticals | 56 | 2021-05-25 | 2025-10-16 |
| Jaktinib Versus Hydroxycarbamide in Subjects With Intermediate-2 or High-risk Myelofibrosis Jaktinib, Placebo to match Hydroxycarbamide, Hydroxycarbamide Tablets - Myelofibrosis | Phase 3 | Completed | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 105 | 2021-02-05 | 2023-11-13 |
| Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis Placebo for Navitoclax, Ruxolitinib, Navitoclax - Myelofibrosis (MF) | Phase 3 | Completed | AbbVie | 252 | 2020-09-29 | 2026-03-23 |
| A Study of Momelotinib Versus Danazol in Symptomatic and Anemic Myelofibrosis Participants (MOMENTUM) Momelotinib, Placebo to match danazol, Danazol - Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis | Phase 3 | Completed | Sierra Oncology LLC - a GSK company | 195 | 2020-02-07 | 2023-11-01 |
| An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib FEDRATINIB, Best Available Therapy (BAT) - Primary Myelofibrosis, Post-Polycythemia Vera | Phase 3 | Completed | Celgene | 202 | 2019-09-09 | 2025-08-28 |
| TAC/MTX vs. TAC/MMF/PTCY for Prevention of Graft-versus-Host Disease and Microbiome and Immune Reconstitution Study (BMT CTN 1703/1801) Mobilized Peripheral Blood Stem Cell graft with Tacrolimus/Methotrexate, Tacrolimus, Methotrexate - Acute Leukemia, Chronic Myelogenous Leukemia (CML) | Phase 3 | Completed | Medical College of Wisconsin | 431 | 2019-06-25 | 2024-04-04 |
| Aprepitant Versus Hydroxyzine in Persistent Aquagenic Pruritus for Patients With Myeloproliferative Neoplasms Aprepitant 80 mg, Hydroxyzine 25mg, Placebo of Hydroxyzine - Myeloproliferative Disorder, Aquagenic Pruritus | Phase 3 | Completed | University Hospital, Brest | 63 | 2019-04-16 | 2025-12-03 |
| Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression Cyclophosphamide, Fludarabine, Total Body Irradiation - Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia | Phase 3 | Completed | Dartmouth-Hitchcock Medical Center | 21 | 2018-03-28 | 2026-07-17 |
| Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs Asciminib, Bosutinib - Chronic Myelogenous Leukemia | Phase 3 | Completed | Novartis Pharmaceuticals | 233 | 2017-10-26 | 2026-08-18 |
| Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard UCB in Patients With Leukemia, Lymphoma, and MDS NiCord® (omidubicel), Cord Blood Unit - Hematological Malignancies, Acute Lymphoblastic Leukemia (ALL) | Phase 3 | Completed | Gamida Cell ltd | 125 | 2016-12-16 | 2026-02-25 |
| Dasatinib Holiday for Improved Tolerability dasatinib (SPRYCEL®) - Myeloid Leukemia, Chronic | Phase 3 | Completed | University of Jena | 291 | 2016-08-01 | 2023-05-10 |
| Study to Assess the Self-administration of AOP2014 Using a Pen, Developed for the Treatment of Polycythemia Vera Patients Pegylated-Proline-Interferon alpha-2b in a Pre-filled Pen - Polycythemia Vera | Phase 3 | Completed | AOP Orphan Pharmaceuticals AG | 30 | 2015-07-01 | 2016-02-17 |
| Optimization of TKIs Treatment and Quality of Life in Ph+ CML Patients ≥60 Years in Deep Molecular Response imatinib, nilotinib, dasatinib - Leukemia, Chronic Myeloid | Phase 3 | Completed | Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia | 229 | 2015-06-10 | 2024-08-13 |
| Stem Cell Transplantation From HLA Partially-Matched Related Donors for Patients With Hematologic Malignancies Radiation, Cyclophosphamide, Donor Lymphocyte Infusion (DLI) - Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia | Phase 3 | Completed | Northwell Health | 10 | 2014-12-01 | 2022-04-07 |
| Expanded Treatment Protocol (ETP) of Ruxolitinib in Patients With Polycythemia Vera Who Were Hydroxyurea Resistant or Intolerant and for Whom no Treatment Alternatives Was Available. Ruxolitinib - Polycythemia Vera | Phase 3 | Completed | Novartis Pharmaceuticals | 161 | 2014-11-21 | 2019-07-18 |
| AOP2014 vs. BAT in Patients With Polycythemia Vera Who Previously Participated in the PROUD-PV Study. Pegylated-Proline-interferon alpha-2b, Best available therapy (BAT) - Polycythemia Vera | Phase 3 | Completed | AOP Orphan Pharmaceuticals AG | 170 | 2014-11-01 | 2021-06-01 |
| Nilotinib ± Peg-IFN for First Line Chronic Phase CML Patients Nilotinib (Tasigna ®), capsules of 150 mg, Nilotinib (Tasigna ®) and Pegylated interferon alfa 2a (Pegasys®) - Chronic Myeloid Leukemia | Phase 3 | Completed | Hospices Civils de Lyon | 200 | 2014-08-01 | 2025-10-02 |
| A Study of Imatinib and Nilotinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase Imatinib, Nilotinib - Leukemia | Phase 3 | Completed | Novartis Pharmaceuticals | 225 | 2014-07-17 | 2019-08-19 |
Showing 20 of 134. Sign in to see all of them.
Leukemia, Myeloid, Acute (51) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (49) · Leukemia (48) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (41) · Leukemia, Myeloid, Chronic-Phase (35) · Primary Myelofibrosis (35) · Myelodysplastic Syndromes (34) · Hodgkin Disease (26) · Leukemia, Myeloid, Accelerated Phase (26) · Lymphoma, Non-Hodgkin (26) · Leukemia, Lymphocytic, Chronic, B-Cell (24) · Multiple Myeloma (24) · Congenital Abnormalities (23) · Blast Crisis (22)
Hemic and Lymphatic Diseases (134) · Hematologic Diseases (127) · Bone Marrow Diseases (126) · Neoplasms (106) · Neoplasms by Histologic Type (104) · Leukemia, Myeloid (98) · Pathological Conditions, Signs and Symptoms (85) · Chronic Disease (84) · Disease Attributes (84) · Pathologic Processes (83) · Leukemia (57) · Immune System Diseases (51) · Immunoproliferative Disorders (47) · Lymphatic Diseases (47)
Cytarabine (24) · Imatinib Mesylate (20) · Daunorubicin (14) · nilotinib (14) · Cyclophosphamide (13) · Peripheral Blood Stem Cell Transplantation (13) · Etoposide (12) · Filgrastim (10) · Hydroxyurea (10) · Methotrexate (10) · ruxolitinib (10) · fludarabine phosphate (9) · Mycophenolic Acid (8) · Cyclosporine (7) · Whole-Body Irradiation (7)
Novartis Pharmaceuticals (19) · Fred Hutchinson Cancer Center (7) · AOP Orphan Pharmaceuticals AG (6) · Alliance for Clinical Trials in Oncology (5) · Children's Oncology Group (4) · European Organisation for Research and Treatment of Cancer - EORTC (4) · Medical College of Wisconsin (4) · Bristol-Myers Squibb (3) · Eastern Cooperative Oncology Group (3) · Incyte Corporation (3) · Memorial Sloan Kettering Cancer Center (3) · National Cancer Institute (NCI) (3) · Sierra Oncology LLC - a GSK company (3) · St. Jude Children's Research Hospital (3) · Case Comprehensive Cancer Center (2)
United States (79) · Germany (41) · France (37) · Italy (35) · Canada (34) · Spain (29) · United Kingdom (29) · Belgium (25) · Austria (23) · Australia (21) · Poland (21) · Czechia (20) · Hungary (20) · Netherlands (20) · Israel (19)
Heinz Gisslinger, MD (3) · Alan K. Burnett, MD, FRCP (2) · Alan S. Gamis, MD, MPH (2) · Brenda Sandmaier (2) · Debra Barton, RN, PhD, AOCN, FAAN (2) · Mary Horowitz, MD (2) · Mary Horowitz, MD, MS (2) · A Bacigalupo, Dr. (1) · A Bosi, Dr. (1)
PMID 31375516, PMID 36184192, PMID 37042865, PMID 39516087, PMID 40535755, PMID 41958363, PMID 23620574, PMID 23911705, PMID 26069290, PMID 28273028, PMID 28962635, PMID 29396713, PMID 32499241, PMID 35235189, PMID 37267439, PMID 37553873, PMID 41890273, PMID 42316774, PMID 42452788, PMID 12637609, PMID 15459300, PMID 15761020, PMID 16484584, PMID 16932345, PMID 16960978, PMID 17151364, PMID 17315155, PMID 17339189, PMID 17397698, PMID 17715389, PMID 18256322, PMID 19117345, PMID 19264678, PMID 19291085, PMID 19369231, PMID 19648168, PMID 19710500, PMID 19797518, PMID 19965667, PMID 20117965, PMID 20131302, PMID 20142590, PMID 20451454, PMID 20496177, PMID 20522709, PMID 20525993, PMID 20525995, PMID 20679528, PMID 20716770, PMID 21175313
U01HL069294 (3), U10CA021115 (3), 2009 (2), 2014 (2), 2018 (2), P01CA018029 (2), P01CA078902 (2), P30CA015704 (2), P30CA068485 (2), U10CA031946 (2), U24CA076518 (2), 2004 (1), 2008 (1), 2016 (1), K23HL084054 (1)